MARKET

VERU

VERU

VERU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.46
-0.48
-5.37%
After Hours: 8.47 +0.01 +0.12% 18:59 09/20 EDT
OPEN
8.56
PREV CLOSE
8.94
HIGH
8.87
LOW
8.35
VOLUME
839.77K
TURNOVER
--
52 WEEK HIGH
24.57
52 WEEK LOW
2.300
MARKET CAP
675.56M
P/E (TTM)
-617.5182
1D
5D
1M
3M
1Y
5Y
BRIEF-Veru Inc Announces Positive Updated Data From Phase 1B/2 Sabizabulin Study At The 2021 Esmo Congress
reuters.com · 14h ago
Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin (VERU-...
GlobeNewswire · 14h ago
Veru Announces Oral Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical data from the Phase 1b/2 study of sabizabulin (VERU-111) in 8...
GlobeNewswire · 09/09 12:30
Veru to Present at Three Upcoming Healthcare Investment Conferences
MIAMI, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the foll...
GlobeNewswire · 09/08 12:30
Investing in These 3 Stocks Could Double Your Money, Says Oppenheimer
Watching the economy today is a bit like watching an evenly matched game of tug-of-war. There are two teams, pulling hard in opposite directions, and it’s a coin toss which will win. In our economic situation, we have sets of tailwinds and headwinds, promi...
TipRanks · 08/24 19:53
Veru Sponsored P2 Clinical Efficacy & Safety Study Of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy For mTNBC Posted To Clinical Trials Website Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05008510
Benzinga · 08/17 13:56
--Oppenheimer Adjusts Veru PT to $26 From $24, Maintains Outperform Rating
MT Newswires · 08/13 11:53
Veru Stock Gains After Q3 Result Tops Estimates
Benzinga · 08/12 17:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VERU. Analyze the recent business situations of VERU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VERU stock price target is 24.40 with a high estimate of 29.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 135
Institutional Holdings: 24.67M
% Owned: 30.90%
Shares Outstanding: 79.85M
TypeInstitutionsShares
Increased
44
2.50M
New
22
1.63M
Decreased
31
5.21M
Sold Out
21
1.07M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Personal Products
-1.04%
Personal & Household Products & Services
-1.04%
Key Executives
Chairman/President/Chief Executive Officer/Director
Mitchell Steiner
Vice Chairman/Director
Harry Fisch
Chief Financial Officer/Chief Administrative Officer
Michele Greco
Chief Scientific Officer
K. Barnette
Independent Director
Mario Eisenberger
Independent Director
Grace Hyun
Independent Director
Lucy Lu
Independent Director
Michael Rankowitz
Declaration Date
Dividend Per Share
Ex-Div Date
03/24/2014
Dividend USD 0.07
04/28/2014
12/16/2013
Dividend USD 0.07
01/27/2014
10/03/2013
Dividend USD 0.07
10/28/2013
07/15/2013
Dividend USD 0.07
07/29/2013
03/27/2013
Dividend USD 0.07
04/29/2013
01/03/2013
Dividend USD 0.06
01/28/2013
10/04/2012
Dividend USD 0.06
10/29/2012
07/13/2012
Dividend USD 0.06
07/30/2012
03/27/2012
Dividend USD 0.06
04/30/2012
01/04/2012
Dividend USD 0.05
01/30/2012
10/06/2011
Dividend USD 0.05
10/31/2011
07/14/2011
Dividend USD 0.05
07/29/2011
04/11/2011
Dividend USD 0.05
04/29/2011
01/14/2011
Dividend USD 0.05
01/27/2011
10/08/2010
Dividend USD 0.05
11/01/2010
07/22/2010
Dividend USD 0.05
08/02/2010
--
Dividend USD 0.05
04/21/2010
01/14/2010
Dividend USD 0.05
01/27/2010
About VERU
Veru Inc. is an oncology and urology biopharmaceutical company with a focus on developing medicines for the management of prostate cancer. The Company operates in two segments: Commercial and Research, and Development. The Commercial segment consists of FC2. The Research and Development segment consists of multiple drug products under clinical development for oncology and urology. The Company's prostate cancer pipeline includes VERU-111, VERU-100 and Zuclomiphene Citrate. VERU-111 is an oral chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules. VERU-100 is a peptide formulation designed to address the limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer. The Company's commercial products include FC2 Female Condom/FC2 Internal Condom (FC2), a product for the protection against unintended pregnancy and sexually transmitted infections.

Webull offers kinds of Veru Inc stock information, including NASDAQ:VERU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VERU stock methods without spending real money on the virtual paper trading platform.